23 Feb Cynata Therapeutics
Mathias Kroll, Ph.D., Chief Business Officer
Oct. 6 | 9:45am | FLW Ballroom G
Melbourne, Australia
(ASX:CYP)
Cynata Therapeutics Limited (ASX:CYP) is a listed, Australian stem cell and regenerative medicine company pioneering a revolutionary approach to cell therapy with our proprietary Cymerus™ platform technology. Developed from research at the University of Wisconsin-Madison, a world leader in stem cell research, our technology harnesses the power of induced pluripotent stem cells (iPSCs) to create a type of mesenchymal stem cells (MSCs) for therapeutic use via a unique precursor cell called the mesenchymoangioblast. Cynata has a rich pipeline with multiple active clinical trials and near-term catalysts including: Phase 2 clinical trial in acute graft-versus-host disease (aGvHD) – currently recruiting globally in final stages Phase 3 clinical trial in osteoarthritis – recruitment complete as of 2023 and last patient visit in November 2025Phase 1/2 clinical trial in kidney transplantation – recruiting patients in the Netherlands Phase 1 clinical trial in diabetic foot ulcer (DFU) – trial complete and results announced in December 2024.
